FDA Expands Test for Gastric and Esophageal Cancers - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.

  • By

  • Kathryn Wighton

  • July 14, 2026

  • 2 min

Share

Original Source(s)

FDA Expands Test for Gastric and Esophageal Cancers

  • by Kathryn Wighton

  • July 14, 2026

Related Content

Inflammatory signatures may distinguish dental caries

Combining IL-17 with TNF-alpha showed strong discrimination between carious lesions and healthy controls, but performance was more modest against gingival inflammation.

AI cuts lesion measurement time by 34%

Automated lesion measurements increased agreement on treatment response, although expert-generated proposals were accepted more often and required fewer adjustments.

Hot drink habits and esophageal cancer

Researchers assessed preferred hot drink temperature and consumption frequency across 2 large UK cohorts.